Clinical Trials
25 trialsNCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT00588770 2026-05-29
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01220583 2026-05-27
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Radiation Therapy Oncology Group
Phase 2 Active not recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02253238 2026-05-20
Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04969835 2026-05-15
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Phase 1 Recruiting
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05669664 2026-05-13
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04325828 2026-05-08
YATAGARASU
Janssen Pharmaceutical K.K.
Phase 2 Active not recruiting
NCT05074940 2026-05-08
Amivantamab in Adenoid Cystic Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT06356272 2026-04-22
Oropharynx (OPX) Biomarker Trial
Mayo Clinic
Recruiting
NCT04620187 2026-04-13
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05075980 2026-04-13
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
Phase 2 Active not recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT05694819 2026-04-08
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Completed
NCT05483374 2026-04-03
EURACAN
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05884320 2026-03-20
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06047236 2026-03-16
ImmoGlandula
University of Erlangen-Nürnberg Medical School
Recruiting
NCT03360890 2026-03-13
iPRIME
University of Chicago
Phase 2 Active not recruiting
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed